The autoimmune blistering disease
Conditions
Interventions
Observation group:None
Sponsors
The First Medical Center of Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Those who have a clear diagnosis of pemphigus and are treated with rituximab combined with systemic glucocorticoids in our department. 2. Voluntarily sign the informed consent form; 3. Subjects who are able to comply with the study protocols and visit plan.
Exclusion criteria
Exclusion criteria: 1. Patients who have had or are receiving rituxib treatment due to lupus, nephritis, lymphoma and other diseases. 2. Patients with incomplete clinical data. 3. Patients who have previously used rituximab for pemphigus disease in other hospitals. 4. At the same time, there are other patients such as dermatitis herpetiformis that affect the evaluation of pemphigus condition. 5. Patients who use systemic or topical glucocorticoids and other immunosuppressants due to other diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pemphigusdiseaseareaindex,PDAI;Complete remission, CRmin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurement of peripheral blood B lymphocyte percentage and absolute count;Autoantibodies against Dsg1 and Dsg3; | — |
Countries
China
Contacts
Public ContactChengxin Li
The First Medical Center of Chinese PLA General Hospital
Outcome results
None listed